A framework for co-creating AI-native health companies sits at the heart of a new alliance between Novo Nordisk (NYSE: NVO) and Cambridge-based data firm nference, announced November 18, 2026.

The venture creation component goes beyond conventional research deals, targeting unmet needs across cardiometabolic conditions and healthy ageing through data-driven startup formation.

Underlying the partnership is a vast pool of multimodal health information, spanning clinical notes, laboratory results, radiology and pathology imaging, and genomic and proteomic data gathered from consented biospecimens.

nference’s federated AI platform will process that data alongside Novo’s own clinical trial records, seeking patterns in how diseases like obesity, diabetes, and cardiovascular disease progress over time.

Precision trials that track weight loss in tandem with broader whole-body health indicators are among the specific research ambitions the two companies have identified.

Clinical pharmacology and combination therapy strategies will also be explored as researchers from both organizations work to close longstanding gaps in treatment effectiveness and long-term patient outcomes.

Jacob Sten Petersen, Group Vice President of R&D External Innovation at Novo, described the potential reach of the initiative: “We see a significant opportunity to use AI and data to deepen our understanding of cardiometabolic disease and help improve future treatments. Our collaboration with nference adds powerful new capabilities to that ambition, helping us connect scientific insights with people’s everyday health challenges.”

nference brings to the table an established network of academic medical center partnerships, including Mayo Clinic, Duke Health, Vanderbilt University Medical Center, Emory Healthcare, Banner Health, Mercy Health, and Rush University System for Health.

Venky Soundararajan, Founder and co-CEO of nference, framed the deal in historical terms: “It is an honor to partner with Novo whose century-long scientific heritage has helped establish modern metabolic medicine. We are excited to uncover new opportunities to benefit patients through Novo’s extraordinary depth of clinical trial research and to translate multimodal discoveries into therapeutic opportunities and new ventures.”

Novo, which employs more than 66,500 people globally, has built its reputation over a century of metabolic medicine research, giving it an unusually deep archive of clinical trial data for the AI platform to interrogate.

All data sharing under the arrangement will operate within defined privacy and governance safeguards, a requirement the companies say is central to the collaboration’s design.

The deal positions nference as a key infrastructure partner for one of the pharmaceutical industry’s most prominent players at a moment when AI-driven drug discovery is drawing intense commercial interest.